Compared to Estimates, Qiagen (QGEN) Q2 Earnings: A Look at Key Metrics

Core Insights - Qiagen reported revenue of $496.35 million for the quarter ended June 2024, reflecting a year-over-year increase of 0.3% and surpassing the Zacks Consensus Estimate by 0.45% [1] - Earnings per share (EPS) for the quarter was $0.55, up from $0.53 in the same quarter last year, exceeding the consensus EPS estimate by 5.77% [1] Revenue Performance by Product Groups - Diagnostic solutions - QIAstat-Dx: Revenue of $24 million, a year-over-year increase of 14.3%, but below the average estimate of $24.37 million [3] - Diagnostic solutions - QuantiFERON: Revenue of $115 million, a year-over-year increase of 10.6%, exceeding the average estimate of $113.62 million [4] - Sample technologies: Revenue of $164 million, a year-over-year decrease of 0.6%, surpassing the average estimate of $160.34 million [5] - Diagnostic solutions: Revenue of $185 million, a year-over-year increase of 4.5%, closely matching the average estimate of $185.03 million [6] - Diagnostic solutions - NeuMoDx: Revenue of $7 million, a significant year-over-year decrease of 36.4%, falling short of the average estimate of $9.32 million [7] - Genomics / NGS: Revenue of $58 million, a year-over-year decrease of 9.4%, below the average estimate of $61.95 million [8] - PCR / Nucleic acid amplification: Revenue of $76 million, a year-over-year increase of 2.7%, exceeding the average estimate of $69.68 million [9] - Other: Revenue of $14 million, a year-over-year decrease of 6.7%, below the average estimate of $14.97 million [9] Revenue by Segment - Molecular Diagnostics: Revenue of $266 million, a year-over-year increase of 2.3%, surpassing the average estimate of $262.74 million [10] - Life Sciences: Revenue of $230 million, a year-over-year decrease of 2.1%, slightly below the average estimate of $231.79 million [11] - Diagnostic solutions - Other: Revenue of $39 million, a year-over-year decrease of 2.5%, exceeding the average estimate of $38.67 million [12] Stock Performance - Qiagen's shares have returned +9.9% over the past month, outperforming the Zacks S&P 500 composite, which saw a -0.4% change [12]